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The Canadian AtrW Fibrillation Antkeagrlatinn Study was a
randomized double-bFmd plaeebureankaied trial to assess the
potential of warfarlb to reduce systemk Ihramboembdtsm and ha
inherent risk of hemorrhage, As a reraY of the pubUcallon of two
other "posltiverr studies of Ainlhr design and objeetise, this study
was ate,.ped early before compktlou of Its planned recruitment of
6.30 patients. There were 187 patients randomized to warfario and
191 to placebo
. Permanent dismntinution of study medication
occurred In 26% of Inrhri-treated and 23 % of placebo-treated
patients. Tie target range of the international normalized rata
was 2 to 3 . For the wadaria .trated patients, the international
normalized ratlo was In the target range 43
.1 % of the study days,
above it 16 .6% of the study days and below it 39 .6% of the study
days. Fatal or major bleding occurred at annual raps of 2 .5% in
waefaeidetreated and 0
.5% i placebo-treated patients . Minor
Atria] fibrillation is common, especially
in the elderly . There
is a well documented (1-3) association between atria) fibril-
lation and systemic embolism
. although estimates of the
absolute annual stroke risk in patients with attial fibrillation
vary from <1% to 8%. In the presence of mitml sienosis, the
risk of stroke in patients with atria) fibrillation is suleciently
high that anticoagulation is usually recommended, even
though there is little supporting evidence fur this treatment
from randomized studies (4)
. However, when mitrat 5termsla
is not present. there is no consensus about the use
of
anticoagulant therapy in attial fibrillation
. The present study
was a randomized double-blind placebo-centrolfed trial of
warfarin in patients with nonrheircatic atrial fibrillation
designed to assess both its potential to reduce systemic
embolism and its inherent risk of hemorrhag
. The protocol
called for recruitment of 630 patients to be followed up on
average for 2.5 years . Part way through recruitment for the
study, the results of similar trials conducted in Denmark (the
Copenhagen AFASAK study (5,61) and the United States
(preliminary reports tram the Stroke Prevention Atrial Fi-
The investigators parvcipatmg in This sandy are tided
on the 1,.pendis.
This
studywassupportedbytheMedi~RcsearchCountyorCanadaandDu
Pant Canada Ltd., Mississaug, Onurio
. Carada .
Manuscript received September
26, 1990 : revised manuscript received
January 21, 1991 . accepted Februar
y
15 . 1991 .
Address forreariatr Shun J . Crtmotlg,
MD
. Hamitiea General Hospita .
237 Barren Street East, Hamilton . Orlatia iSL 2%2 . Canada .
ulvsl by the American Cdtese arC -ivlvsy
349
bleeding occurred In 16% of patients receivlug warfarin and 9%
receiving placebo . The primary outcome event cluster was mama .
cunar stroke, rloncentral nervous tystemle embolism and fatal or
intraeranlal hemorrhag . Events were included i the primary
analysis of efficacy If they occurred within 28 days of permanent
dtseondnuatioa of the study medksfion
. The annual rates of the
primary outcome event duster were 3 .5% i wartarin-treated and
5.2% In placebo-treated patients, with a relative risk reduction of
37% (95% confdetce knits, -63 .5%, 75.5%, p = 0
.17). This
esseatate of benefit of atlicnagalust therapy En aerlad fibrillation is
consistent with the estimates from previous reports and supports
the use of warfadn in patients with nonrhnmatic valvulor atrial
fibrillation for the prevention of systemic thrornboembdhm .
(J An
Coif Card of
1991 ;18 :349-55)
brillation
ISPAFI
study 131) became available, With the
publication of the second "positive" trial, the Steering
Committee believed that the cumulative evidence of antico-
agulant
efficacy
in this catilitlon was sufficiently persuasive
to warrant the early termination of the present study after
randomizing only 393 patients
.
Methods
Patient selection. This study was carried out between
June IY87 and April 19911 in I I Canadian centers . The study
uas approved by the Institutional Review Board of each
center . Potentially eligible patients were identified by the
screening of electrocardiograms (ECGs) in participating hos-
pitals and associated outpatient laboratories, as well as by
direct referral
from physicians . Patients met the inclusion
criteria of the study ifthey satistted the following: I) chronic
atria) fibrillation documented to be present for al month or
paroxysmal aerial fibrillation occurring at least three times in
the previous 3 months (documented at least twice on the
ECG) : 2) age >_19 years; 3) absence of any mitral valve
prosthesis or mechanical aortic valve prosthesis
; and
4) absence of mitral valve stenosis on two-dimensional
echocardiography. Patients were excluded from the study
for any of the following: 1) reovirement for anticoagulation ;
2) medical coptraindication to anticoagulation; 3) stroke or
transient ischemic attack within I year ; 4) requirement for
0735-1097NI43.59
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anliplatelet drug therapy ; 5) hyperthyroidism ; 6) uncon.
trolled hyperensiou, and
7)
myocardial infarction within
I month .
Eligibility . Before randomization, a baseline evaluation
was performed . con.isting of a relevant medical history,
cardiovascular and neurologic examination by an internist
and laboratory evaluation including an ECG, two-
dimensional echocardiogram, hemoglobin
. platelet count,
prothrombin and partial prothrombin times
. serum thyroid
and thyroglobulin binding and urinalysis . Randomization
was effected by the strict sequential use of medication
packages containing 5 mg tablets of warfarin (Caumadin) or
matching placebo according to a predetermined random
order .
Anticoagulation . All patients had periodic measurement
of the prothrombin time to regulate the dose of the study
medication
. The study was carried out in a triple-blind
manner (patients. investigators, coordinating center). In
each clinical center, there was an unblinded anticoagulation
supervisor who received the results of the prothrombin time
measurements . This supervisor regulated the dose of the
study medication for patients on active treatment to maintain
an international normalized ratio in a range of 2 to 3 . For
patients receiving placebo, the results of the prothrombin
time test were ignored and, instead, the dose of the study
medication was modified according to a series of sequential
"sham" prothrombin time results
. prothrombin time teas
were done no less frequently than every 3 weeks
. After ea ;h
prothrombin time determination, the anticoagulation super-
visor indicated what changes in study medication dose were
required. The study nurse then informed the patient of Fhe
new dose
: the anticoagulation supervisor never contacted
the patient directly . In
general, patients were free to cho :use
the laboratory to be used for prothrombin tests .
Most laboratories used in the study did nut report the
prothrombin time result as an international normalized rain .
A nomogram based on the type of thromboplastin ann the
normal range of prothrombin time was used to determine for
each laboratory the therapeutic range of prothrombin results
corresponding to an international normalized ratio in the
range of 2 to 3
. To maintain blinding, patients admitted for
elective surgery had administration of the study oedication
discontinued ?6 days before admission and restarted at
hospital discharge . At the discretion of the investigator,
patients who were admitted to the hospital for other reasons
often had the study medication discontinued temporarily
during the hospital stay to reduce the risk of unhlinding . In
addition to regular telephone contact by the nurse to convey
any change in the dose of study medication, patients were
also seen at 6 weeks and at 3 months after randomization and
then every 3 months thereafter
. At these scheduled visits,
blood pressure and an ECG were obtained and the patient
was questioned as to the prevense of any nesv symptoms
indicative of systemic embolism or bleeding .
Bleeding events- Patients were requested to imnsedLtely
report bleeding episodes of any type to the study nurse .
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Bleeding episodes were categorized as follows : 1) a life-
threatening bleeding eveni was defined tube any intracmnial
or fatal bleeding
; 2) a major bleeding event was defined as
any bleeding episode associated with a m20 glliter decrease
in serum hemoglobin or requiring a blood transfusion or
bleeding into a sensitive location such as the pericardium or
retina; and 3) all other bleeding events were considered
.nirtor . In the event of life-threatening or major bleeding, the
study medication was permanenliy discontinued . For minor
bleeding, the study medication was stopped for s 3 days and
then resumed m a time and dose decided by the anticoagu-
lation supervisor . For the purpose of analysis, bleeding was
considered to have occurred during rrvttment with the study
medication if it took place before or within 7 days of study
medication discontinuation.
Outwore events. A primary outcome event was the first
occurrence of any of the following: 1) any ischemic stroke
except lacunar; 2) other systemic embolism to the gut,
kidney, legs or arms ; and 31 intracranial or fatal hemorrhage .
Secondary outcome events were : 1) transient ischemic at-
lack; 2) lacunas' infarction; 3) maier bleeding ; 4) minor
bleeding ; and 5) death . Stroke was defined as the sudden
onset of a new neurologic deficit lasting m24 h, including :
1) weakness or sensory impairment of the legs, arms or face ;
2) speech impairment ; 3) temporal spatial impairment ; 4)
visual loss ; 5) two or more of a) incoordination, b) cranial
nerve abnormality, and c) dyswthria ; or 6) objective and
persistent worsening of a previous deficit, with an appropri-
ate new finding on computed tomography of the head .
Lacunar infarction was considered to
have occurred when
alt of the following were present : I I arterial hypertension; 2)
typical clinical findings (pure motor hemiplegia, pure sen-
sory stroke, ataxia hemiparesis and dysarthria-clumsy hand
syndrome); and 3) computed tomography of the h .ad show-
ing a small (<I cm), deep infarction or no abnormality.
Noncentral nervous system embulic events had to h .° docu-
mented by typical findings on angiograpfay or at surgery.
Transient Ischemic attack was defined as abrupt onset of a
focal nearologic deficit lasting >i min and <24 h within the
territory of a single major brain artery. A stroke was
considered severe if I month after the event, the patient
required assistance to eat, walk or communicate . A com-
puted tomogram of the head was not required for the
diagnosis of stroke and was not routinely performed
.
Data analysis. The study plan was to enter 630 patients
over 4
years, with follow-up evaluation to a common end
point at 5 years . The sample size was calculated, assuming a
one-sided alpha of 0.05 and an expected event rate of
5 .6%lyear in the placebo group to give 80% power to detect
a risk reduction by treatment of 5090. Formal notification of
permanent discontinuation of the study medication initiated
a 28-day waiting period . The primary analysis of the study
was planned to be an "efficacy" analysis in whirh events
occurring >2S days after formal notification of permanent
discontinuation would be excluded . When medication was
temporarily discontinued . events occurring during that pe-
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rind were : .eluded in the analysis of efficacy . When a
temporary aiscontinuation progressed to a permanent dis-
continualion, the 215-day waiting period began not at the time
of temporary discontinuation, but at the time of formal
notification of permanent discontinuation . A comparison of
the rates of primary outcotr;c event5 Using the "rnlenhon to
treat" principle was planned as the most Important second-
ary analysis
. An interim analysis of efficacy by the External
Safety and Efficacy Monitoring Committee was planned to
occur once 50% of the total expected patient-years of
follow-ur had aceunaulated, but this point was never
reached,
Standard analysis techniques for failure bras data were
used. The proportion of patients in each treatment group
remaining event free over time was estimatesc using the
Kaplan-Meier estimator (?)and compared using the Mantel-
Haenszel teses (8) . Confidence intervals for risk reduction
were derived from the Curs proportional hazard model 191 .
To compare our results with those of other studies, observed
hazard ratios were calculated from published rerulls of the
Stroke Prevention in Atrial Fibrillation Study (3), the Copen-
hagen AFASAK study )5,6) and Boston Area Anticoagula-
lion Trial for Altial Fibrillation (101 . Approximate 95%
confidence intervals were computed for the natural loga-
rithm of hazard ratio as: fog (observed hazard ratio) ± € .96
tld
l!d,,,gl I), where dand d, are the number of e'rnnts
observed in the placebo and warfarin groups, respectively
.
The conversion to the corresponding confidence interval for
isk reduction was achieved by exponentiating am : then
subtracting l . The degree of anticoagulation achieved n this
trial was summarized by calculating the mean international
normalized ratio and the proportion of international m rrmal-
ized ratios in the therapeutic range for each patient
. Both
were weighted by the time gap between successive determi-
naliansof the international normalized ratio and restricted to
the period >90 days after randomization when initial stabi-
lization should have occurred . Individual patient values of
the mean international normalized ratio and percent of days
in the therapeutic range were then averaged fnrall patients in
the active treatment group to produce a summary Caustic .
Values are presented as mean values ± SD
.
We performed detailed darumenretian
rf the rea sans for
exclusion for all patients who met the inclusion criteria
between November 1987 and June 1988. during which time
1 .430 patients were screened . After that time
. detailed
documentation of exclusions was done only for a selected
sample
. (N the 1 430 patients screened who met the study
inclusion mite& . 179/ had a contraindication to oral anrien-
agulation, 291 required anticoagulation . 17% required an
antiplatelel drug, 4% had chronic alcoholism . 35`1 had a
social-psyehulogical reason for not participating and 125E
were excluded for other reasons, Of the 13
°91 who were
eligible, 541i gave consent and were randomized. Six per-
cent of patient meeting the inclusion criteria entered the
study
. A committee of blinded coinvestigators reviewed the
eligibility of all patients and all reposed outcome events .
Table 1. Baseline Patient Characteristics
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'Vala,, arc man - 5D . A F = strict fibriati- LA = left a trial: LV =
left sersricular: TIA =
transient
salamis attack .
Results
Sandy patients and basellue characteristics . Three hun-
dred eighty-three patients entered the study ; five (two ran-
domized to warfarin and three to placebo) did not have aerial
fibrillation or had initial steeosis and were judged by a
blinded adjudication committee to be ineligible . Thirty-seven
patients (24 randomized to warfarin and 13 to placebo) were
judged to have atrial fibrillation but were technically ineligi-
ble as a result
of a minimal violation of the entry criteria . All
eligible and technically ineligible patients were included in
the analysis ; 197 were allocated to warfarin and 191 to
placebo. No outcome events occurred in the five ineligible
patients . The mean follow-up period was 15 .2 months.
Table I summarizes the baseline characteristics of the
patients randomised (o warfarin or placebo . Although the
randomization procedure provided reasonably comparable
groups . there was a tendency for the warfarin group to
contain more patients with diabetes mellitus . intermittent
ctaudication, previous vascular surgery and arterial vascular
bruit
. Early permanent discontinuatiom of the study medica-
tion DO due to a primary outcome event occurred in 49
warfarinarcated patients (26.2%) and 43 placebo-treated
patients
The causes of permanent discontinuation
were patient or physician preference (30 in the warfarin and
22 in the placebo group), requirement for the contraindicated
drug (9 in the warfarin and 10 in the placebo group), bleeding
~4 in the warfarin and 2 in the placebo group) and other
causes (6 in the warfarin and 9 in the placebo group) .
Temporary discontinuation of the study medication for >7
days occurred 58 times in 47 patients receiving warfarin and
WarfarinGmup
is = 1811
PiacehaGram
In - 191,
Agelyrl•
68.0-9.7 67.4x9.6
"MI c4.1 759 73
.3
Annaf0I 219 19
.9
Pam,ntucu4ialinfarclianl0) 15.0 12.0
lean failure let 23.5 20.4
Stroke or TIA I I 3.2 4.2
7Memillsr,rlaaw[anonrit 10.2 47
Dotetes relliWS101
13.9 14.0
Cardiemyapthyl%t
6.4 $.8
H'-'y d 6 rp<tssk 1"1) 43 .3 340
LA dimendantmmi 455 a±8.t 46.0x9
.3
Lv rnddo4ohc dtmraswn (mml
• 52
.4 ! 7.8
51 .6 9.0
Anmialvascatarbruitl%a) 11 .8 6 .8
Years since is-is of AF (53)
<I 19 .8 18 .3
I-1 24 .6 25 .7
4-6 17
.1 173
~e 38.0 38.2
L'nkaa.s 4.5
Parusysmai AF 1701 6.4 7.3
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Table 2. Oateome Events in the Two Treatment Groups
CNS = serest nervous system
; TIA = tramient inherit attack .
78 times in 52 patients receiving placebo . The resultant
proportion of days of study follow-up in which patients were
not receiving the study medication because of temp, rary
discontinuation was 5.8% for the warfarin group and 6.1%
for the placebo group. The most common reason for an
episode of temporary discontinuation of the study medica-
tion was a surgical procedure (44
.8%).
Anticoagulation and bleeding . After an initial 90-day pe-
riod of stabilization, the mean dose of the study medication
was 4 .6 ± 1 .9 mg/day for warfarin and 5 .6 ± 2 .6 mg/day for
placebo . The target range of the international normalized
ratio was 2 to 3 and the mean international normalized ratio
for warfarin-treated patients was 2 .4 ± 0.4 . The estimated
percent of days during which the international normalized
ratio was between 2 and 3 was 43.7%; the ratio was below
the target range 39 .6% of days and above ii 16.6% of days .
The effectiveness of blinding of therapy was assessed by
having cuinvestigators report all cases of unblinding . Un-
blinding of the patient, the family physician or study person.
nel was reported in 17 warfarin-treated patients and 12
placebo-treated patients . Patients were excluded from entry
if they required aspirin or antiplatelet therapy and patients
were advised not to take these agents during the study .
Rarely, patients with an acute
exacerbation of arthritis
received a brief course of ibuprofen .
Life-threatening or major bleeding during receipt of the
study medication occurred in five patients receiving warfarin
and one patient receiving placebo ; one other major bleeding
episode occurred 524 days after permanent discontinuation
of medication in a
placebo-treated
patient . The annual rate of
fatal or major hemorrhage while patients were receiving
study medication was 2 .5% in those receiving warfarin and
0.5% in those receiving placebo
. Two of the bleeding epi-
sodes during administration of warfarin and none during
placebo administration were fatal . The international normal-
ized ratio for the patient with a fatal intracranial hemorrhage
was 3.5 2 days before the event and that of the patient with
Elrcaey Amlyua Intention m Trca1 Amtysi,
IACC Vol 18. No. 2
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a fatal ruptured abdominal aorta was 2 .6 1 day before the
event ; the ratios recorded immediately before the three other
major bleeding episodes in the warfarin-treated patients
were 2 .7, 1 .5 and 2.1
. Minor bleeding occurred in 16% of
warrarin-treated patients and 9
.4% of placebo-treated pa-
tie .lts.
Efficacy . Table 2 shows the primary and secondary out-
core events occurring I) up to 28 days alter permanent
discontinuation of the study medication (efficacy analysis),
and 2) at any time during the study (intention to treat
analysis) . With the efficacy approach, the annual rate of the
primary outcome event cluster in patients receiving warfarin
or placebo was 3.5% and 5 .2%. respectively . The relative
risk reduction was 37% (95% confidence limits -63 .5%,
75 .5% ; p = 0,17) . One additional primary outcome event
occurred in a patient randomized to warfarin SOB days after
permanent medication discontinuation and was counted in
the intention to treat analysis, yielding an annual event rate
of the primary outcome event cluster for warfarin and
placebo of 3 .4% and 4 .6%, respectively, with a relative risk
reduction of 26% (95% confidence limits -83 .6%, 70.4% ;
p =11.25) . When the efficacy analysis of the primary outcome
event cluster was adjusted for differences in the distribution
of baseline characteristics, the estimated risk reduction
increased slightly to 45% (95% confidence limits -46%,
79 .1%; p = 0.12) . The annual rate of the event cluster of
nonlacunar stroke or noncentral nervous system embolic
events by the efficacy approach was 2.5% and 5 .2% for
wuefarin and placebo, respectively, and the risk reduction
was 55% (93% confidence limits -39.4%, 84 .3%
; p = 0
.07).
Figure I shows the cumulative risk of primary outcome
event cluster and of the cluster of nonlacunar stroke or
nancentral nervous system embolism using the efficacy
approach.
Of the six nonhemorrhagic primary outcome events in the
warfarin group, only one occurred in a patient whose
international normalized ratio was in the target range . One
watronu Greap ilaceboGroup
4n=1911
WarfanoGroep
In=1371
PheeboGroup
(n=1911
tkimary merit
NM-stroke 4 9 5 9
SonCNSembolic
I
2 I 2
vent
tmeaaanial hsororrhage 0 I 0
olhn, foist henrorrhage
Told
a
I1
I
a
o
II
Secondary remit
TIA i 2 2 2
Laminar stroke I 0 I 0
vascular death 6 6 9 6
Otho: death I 0 I
2
Total 9 a 13 10
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Figure L Cumulative rate of events lot the two event clusters .
CNS = central nervous system: P = placebo
: w' =
.darn
event occurred 508 days after permanent discontinuation of
the study medication and four occurred in patients without
permanent discontinuation of the medication but with an
international normalized ratio below the target range (inter-
national normalized ratio 1, Lt
. 1
.1 and 1 .4)
. One of these
events occurred on the day of study entry and another
occurred during temporary discontinuation of medication
.
Six of the nonlacunar strokes were judged to be severe
(two in warfarin-treated and four in placebo-treated patients)
and eight were mild Ithree in waifarin-treated and five la
placebo-treated patients) . One noncentml nervous system
embolic event tin a warfarin-treated patient) recluir-d leg
ampwation and one (in a
lacebo-treated
parlour) required
bowel resection- The only patient diagnosed to have a
kwunar stroke subsequently had a nonlacunar stroke while
taking the dodo medication
Discussion
Reasons for early discontinuation of the Idol. When the
present study was i nitiated . it was uncertain whether anti-
coagulant therapy was effective in reducing the risk of
systemic embolism and whether the balance between the
risk and benefit of this treatment was favorable
. After
recruitment of W7c of the anticipated patients and before
achieving 50ct of the anticipated patient-years of follow-up .
results of the :.openltagen AFASAK study (5) and the
CONNOLLY ET AL .
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Stroke Prevention in Atria) Fibrillation study (3) were pub-
lished . showing warfurin to significantly reduce the risk of
systemic embolism. We considered these studies to be
methodologically strong and reasonably similar In the
present study in terms of the patient cohort studied and the
hypothesis tested . We concluded that the previous uncer-
tainly concerning the value of anticoagulation in patients
with nonrhuumalic atria) fibrillation had been greatly re-
duced and that it was no longer ethically possible to justify
withholding anticoagulant therapy from our study patients .
The oecisien t0 terminate the present study was made by its
Steering Committee without knowledge of the study results .
This decision was based on the argument that such knowl-
edge would not alter the decision to stop the study because
whether or not there was a trend in favor of warfarin, the
confidence limits of the estimate would he wide and would
almost certainly encompass those of the other published
studies
. Conversely, if the results showed a trend favoring
placebo, continuation of the study to confirm a detrimental
effect of Therapy could not be justified. More recently, the
Boston Area Anticoagulation Trial for Atria) Fibrillation (FO)
reported an 86% reduction in ischemic stroke and systemic
embolism with warfarin compared with usual care .
Comparison with previous studies. Although the previ-
ously published studies (3.5 .10) are similar to the present
study in many respects, there are several differences . Only
the present study was double-blind in design. Although
logistically more complex, double-blind management of an-
ticoagulation was successful in this study and provided a
methodela loony stronger approach through reduction of
potential bias in the assessment of outcome events . The
target range of the international normalized ratio for
promthrombin time was 2
.8
for the Copenhagen study
(5) . 2 to 3.5 for the Stroke Prevention in Atria) Fibrillation
study (3) • 2 to 3 for lire present study and LS to 2 .7 for the
Boston study 1101 .
M,ayar hemorrhage ryas defined s(ighrty differently in
these .studies, bar the rates can he reasonably compared .
the anual rates of intracranial and major bleeding in
patient, rceeiving placebo or wadarin, respectively, were
0.49 and h .8% in the Copenhagen study (5),
0
.9% and 1 .7%
in the Stroke Prevention in Atria) Fibrillation study (3) and
0Svf and LAI/ in the present study. Surprisingly, the rate of
hemorrhage is somewhat lower in the Copenhagen
AFASAK study 15) despite the higher target range for the
international normalized ratio and higher mean age of the
study patients .
It ii obi tons that the ace of anticoagulant therapy in
patient u with
atria)
frbrillatian impiiet
a tradeoff henceen a
reduction is systemic thramboembalfsm and an increase in
seriuas ilentarrhage . A study design that chooses to focus on
the more biologic question of whether anticoagulation can
reduce thromboembottsm would exclude bleeding from the
primary aaalysis and a study design more interested in the
individual patient would include fatal orintrueranial bleeding
in the primary analysis . When comparing the results of the
Nan-Lacunae Stroke,
Nun-CMS Embolic Events, Falat
15-.
or tnlracranlal llrmocrhage
. .. . .. .. .. ... ..
pnv. „I
to-
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Table 3. Comparison With Published Studies'
This comparison uses the intention to treat approach. includes isd.raac slmke and other systemk thmmbonm
holism and
-'"de,
transient Isehemie attack and hemorrhage . tASwrnes that half o the acree coons! during aetIve
vealment in group I of the Stroke Pmvention in Amal Fibrillation ISPAF) preliminary report arc vlcihutahle 10
warIarin. Stile control group in this study secewed "usual cart ." AFASAK - Copenhagen AFASAK Study;
aAATAF
- Boston Area Amicoagulalian Trial for Atria) Fibrillation : CAFA -
Canadian Aural Fibrillation
Anlicoxgulalioe Study .
present study with those of other studies, one must consider
the important differences in the composition of the primary
outcome event clusters and type
of analysis (efficacy or
intention to treat) . Whereas
the Copenhagen AFASAK
study
(5) used an efficacy approach and included both
transient ischemic attack and intracranial hemorrhage in the
primary analysis, both the Stroke Prevention in Atrial Fibril-
lation study (3) and Boston Area Anticoagulation Trial for
Atria] Fibrillation (10) used an invention to treat analysis and
included neither event. The primary analysis of the present
study used the efficacy approach and included fatal and
intracranial hemorrhage
.
Table 3 compares the present results with those of the
Stroke Prevention in Alriat Fibrillation study (3). the Copen-
hagen AFASAK study (5 .6) and the Boston Area Anticoag-
ulation Trial for Alrial
Fibrillation (10).
To
balance the
comparison, the data of all of the studies are presented using
the intention to treat principle . This comparison also ex-
cludes hemorrhage and transient ischemic attacks so as to
examine the more purely biologic question of whether anti-
coagulation can reduce systemic thromhoembolism. Be-
cause the Stroke Prevention in Atrial Fibrillation study
preliminary report (3) combines the events occurring during
administration ofwarfarin and aspirin (active treatment), the
risk reduction fur this study is estimated assuming that half
of the seven events occurring during active treatment are
attributable to warfarin. It is apparent from Table 3 that the
Confidence limits of the risk reduction for all the studies
overlap to a great extent .
Impli afinns . The consistency
of
the estimates of reduc-
tion in risk of systemic embolism and the relatively low rates
of major hemorrhage in all of the published studies strongly
support the use
of warfarin in patients with atrial fibrillation .
Although aspirin reduced thrumboembolism in the Stroke
Prevention in Atrial Fibrillation study (3), it was not benefi•
cial in the Copenhagen AFASAK study (5) . It has been
suggested that the negative result of the Copenhagen
AFASAK study may be due to the older patient age or the
lower dose of aspirin used in that study . Although aspirin
therapy may at present be preferred in patients al high risk of
hemorrhage, the evidence supporting the use of
wadiarin in
patients with atrial fibrillation is much stronger than that
supporting aspirin
.
Appendix
IACC Vol . IS. No. 2
August 1991 :349-53
CgeWs Atrkl FbrRMhn AatkngnWioe Stas PgrUditsmis
McMWer'Jntrenity, HrRraa, Ontslo: Stuart J . Carnally. MD,
FRCPC. John A. Calms. MD. FRCPC . FACC. Akaanderes. G . Turpie, MD,
FRCPC, John E. Paulstlh, MD, FRCPC, Elaine P. Gosdun, MD, FRCPC.
Past H. Taoser, MD, FACC, FRCPC, Brian J . Staley, MD. FRCPC. Loran S.
Fnkelstein, MD, FRCPC. Rusk Carron, RN. Gayle Stanborouoh, RN.
University d Wake Oslrla, Lands,Orrta: Andreas Laupacis. MD.
FRCPC, Robert K. Stoart, MD, FRCPC. Vladimir C. Haehimki, MD,
FRCPC, Libardo J . Melee ee, MD. FRCPC . Larry M . Browmaernbe, MD,
FRCPC, Michele D. Goddard. MD, FRCPC, Helen Miekesy, RN .
UdvereRy or Tarnro, Tareme, Orad,: CampbcU Joyner, MD, FRCPC,
lama D . Dobbin, MD, FRCPC, John A. Blakely. MD, FRCPC. John A .
Norrs, MD . FRCPC, Lye Ballem RN .
Udnnay d Dust", Onm, Galaria, Martin Green .
MD, FRCPC,
Donald S .
Brasande . MD, FRCPC
. Nancy Simmons. RN .
University d I tYk Calm". Vncwver . British Cakasbla; Charter
Ken, MD, FRCPC, John Boone. MD, FRCPC. IoM Yeung. MD. FRCPC.
William Martin, MD. FRCPC. Stephan Clarke . MD. FRCPC. Susan Mooney.
RN,
UefrtmYy, d Madtaha, Winnipeg, Masimbe : Andrew Morris, MD,
FRCPC, Mlarael Fmis. MD . FRCPC. A . Majid 9hgania, MD. FRCPC. Joy
MacKenue, RN
.
McGN Davenlq Mammal. Qwhee: Kenneth Fegerl, MD. FRCPC,
Jaime Coon, MD, FRCPC. Antrim. Hatir,, MD, FRCPC,
Party Tremblay-
Maraaix. RN, Nartuth Hehert, RN .
DalhousieUulmsit,,Hdgaa,Novass.W:Eli bethMann,MD,FRCPC,
K . Sue Rob..", MD, FRCPC, Orphan Phillips, MD, FRCPC, Barbara
Grant, RN .
Queue Usla niq, Klepron. Onkria: John Parker, MD . FRCPC. John
Milliken
. MD
. FRCPC, Andrew Koval, MD, FRCPC . LyaJa Reid . RN,
MeisuW Ualneraky, SL Jnha's, Nesrfunudlsd, Borer Sussex, MD,
FRCPC, William Pryse-Phillips, MD. FRCPC. Lucindu Whiln®n, MD,
FRCPC, Kathy Murphy, RN .
University or Montreal, Longeell. Quebec : lacquer Lcnii. MD. FRCPC,
Lauren) Belanger, MD . FRCPC, Ardre tbnard, MD, FRCPC, Colette Lcmay,
RN.
Sde% Manltorleg Committee, HaSloe, Ontario : George Carruthers,
MD, FRCPC, Neville Bares, MD, Wayne Taylor, MA
.
Caardiaa legend Methods Centre, Haatov, Good .: Michael Gent, DSO,
Robin Roberts, MSc, Annette (Snip) Mesquite, Harvey Nelson, Shelley Ire .
Study
freferencel
Observed Events Bask Reduction
Placebo Warforin Observed 95%Cl(approxl
SPAF0) 111 3.51 81 .6 42.1%,94 .l%
AFASAK 22 9 10.0% 1199, 81%
15 .6)
BAATAF 13t 2 66% 51% .96%
(1n)
Present nudy I I 6 44 .8% -499%,79.n
JACC V.I. IS. No.2
ADMn 1991 :349-55
References
I Kare el WB . Abbott KID, Savage DD . MoNamam PM. Coronary hear
disease and aerial l.brikmom. the Fnminghmn 11dy-Am Heat J 1913 :
106:189-%.
2. Kopeaky SL, Gerch El, McCoon MD . I al. The nawral lost: ey nt I-
W64 hb,illadon. N but I Med 1987917 :6119-14 .
3. Special Report : preliminary report cf the Stroke Prevenhon in Ainal
fihrglmiao study . N Est J NW 1990.32 1 86"-
4. Dent M . Akxander J, Dc Slva R . Kill- F . AntilhramLaric therapy in
atdal bbrifaoon. Chest 19fE .891supplTf$5 745
5. Peo-rare P, Buyeen O, GadIEsdeen I . Andersen LU, Andersen [L
Placebo-ennlrollen. rardo,na l Inert of warfand and
or-
ynr
pr .
...n .
bon of thromhanabola cmnplicatiane in chronic elr :ri hb,its:. an : the
CepeeblAce AFASAFI study. Lancet 1959 :1 .17511
.
CONNOLLY ET AL .
	
355
CAFASTUDY
b . Perersen P, Boy- G . P,-,ion of woke in abed fibrillation rleanS .
N Fill J bled 1997:323 :482.
7 . Kaplan FL. Meier P. Non.paeomelic eoimaian €ram incomplete oksen
rrtons. 1 Am Sral Asses 195833.457-81 .
8 . Hmrcei N. E .dualien el surrivd da :aand two new rank order statinics
arisirg m v, -id- lien Cancer Chemmher Rep 1966 :50'163-70.
9 . Cm DR ItnEvennor nodeS eel Air 1051,1 1101SF slls105stos) Ill Slat Foe
0 1972 :34:187--221.
10 Boston Area Anticaagulmien Taal far Atnal Fibrillation Investigators .
The rRa , of
load- w,fari, on the risk of shako is nmnrlreemaGc
auul firrillarioe . N Engl 1 Med I990 .323 :IWt I3 .
il, M11,11 -h JD, Prenl¢e RL . The SSelislical Analysis of Failure Time
Data . NY : lines Alley, PA4l'49 9l
